Initial Experience: Alleviation of Pain with Percutaneous CT–Guided Cryoablation for Recurrent Retroperitoneal Soft-Tissue Sarcoma

Fan, Wenzhe; Niu, Lizhi; Wang, Yu; Yao, Xuehua; Zhang, Ying-Qiang; Tan, Guangming; Yang, Jing; Li, Jiaping

doi:10.1016/j.jvir.2016.06.034

Cited by 12 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have mentioned risk factors for local recurrence after cryoablation. Fan et al demonstrated signi cantly poorer prognosis for large tumors (≥ 10 cm) than for small tumors (< 10 cm) in a study of recurrent retroperitoneal soft tissue sarcoma [23,24]. Oligometastasis and a larger difference between maximum cryoablation diameter and tumor diameter were signi cant predictors of good control [19].…”

Section: Discussionmentioning

confidence: 99%

“…For sarcomas, LPFS rates for recurrent or metastatic lesions at 1, 2, and 3 years were 82.09%, 59.70%, and 46.29%, respectively [22]. In particular, local control is di cult to achieve for recurrent retroperitoneal soft tissue sarcoma, resulting in LPFS rates of 94.9%, 56.4%, and 7.7% at 6 months, 1 year, and 2 years, respectively [23]. In our study, local control rates with soft tissue lesions were 72.5% at 1-3 year.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cryoablation for malignant bone and soft tissue tumors and histological assessment of ablated tumors

Asanuma,

Nakatsuka,

Nakamura

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Recurrent or metastatic disease after completion of initial therapy for primary sarcoma represents a substantial problem, along with as well as metastasis of cancer. Cryoablation is a new, minimally invasive option for local antitumor therapy that is attracting attention regarding relationships with the immune system. The purpose of this study was to evaluate the efficacy of cryoablation for local control of bone and soft tissue lesions, to elucidate risk factors for recurrence, and to clarify histological changes of necrosis and immune cell invasion after cryoablation. Methods: Participants comprised 25 patients who underwent cryoablation for 53 discrete lesions of bone or soft tissue recurrence after resection or as metastases of cancer or sarcoma. Local progression-free survival was evaluated after completion of cryoablation. The histology of tumor tissues resected after cryoablation was assessed for 7 cases. Tumor tissues after cryoablation was resected for 7 cases. H&E staining and immunostaining for CD4, CD8, CD68, CD16, CD204, IDO, and CD47 were performed. Results: Local progression-free survival rates were 88.1% at 1 year and 79.7% at 2 and 3 years. Risk of local progression was significantly higher for recurrent lesions after resection, and for lesions ≥4.0 cm in diameter than for metastatic lesions, or lesions <4.0 cm, respectively (p<0.05 each). In subgroup analysis of bone lesions, lesions with an extraskeletal component tended to be associated with worse local recurrence-free survival than those without an extraskeletal component (p=0.135). On histological examination, tissue in the ablated area was completely necrotic. In the border area between ablated and non-ablated areas, CD68-positive cells were more frequently observed than T cells. CD16-M1-like and CD204-positive M2-like cells were observed. Conclusions: Cryoablation demonstrated good anti-tumor efficacy without distinction of tumor types and bone. Local control for recurrent and lesions ≥4.0 cm in diameter was inadequate with cryoablation. Further analysis for the relation between macrophage and cryoablation is needed and may provide critical information about a superior anti-tumor effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cryoablation for malignant bone and soft tissue tumors and histological assessment of ablated tumors

Asanuma,

Nakatsuka,

Nakamura

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…However, cryotherapy can be successful for the management of symptomatic retroperitoneal sarcoma relapse, for example. Therefore, Fan et al were able to report a significant pain reduction from 7.49/10 to 5.44/10 (p = 0.01) on a visual analog scale after cryotherapy of cases of retroperitoneal sarcoma relapse [61].…”

Section: Musculoskeletal Systemmentioning

confidence: 98%

Current Technique and Application of Percutaneous Cryotherapy

Mahnken

König

Figiel

2018

Fortschr Röntgenstr

View full text Add to dashboard Cite

ABSTR AC TPurpose Local ablative therapies have become an established treatment option in interventional oncology. Radiofrequency ablation (RFA) and microwave ablation (MWA) are a standard of care in the treatment of hepatocellular carcinoma (HCC). Currently, there is an increasing interest in cryotherapy, one of the oldest ablation techniques. It has some unique characteristics with regard to technology and mechanism of action.Materials and Methods A systematic literature search using the terms cryotherapy, cryosurgery and cryoablation was performed. Selected studies are presented dealing with the mechanism of action, cryobiology and clinical use of percutaneous, image-guided cryoablation. Recent developments and perspectives are presented.Results Cryotherapy is increasingly used and has been included in guidelines for selected tumor entities such as renal cell carcinoma. Cryo-immunotherapy and combination treatments are future areas of interest.Conclusion Cryoabalation may be used in many indications.Its major advantages are its unique visualization and the anesthesiologic effects of cold. While there are only a few prospectively randomized trials, the existing data on the use of cryoablation is promising. Its use appears to be justified in selected tumors, oligometastatic patients and for palliative indications.

show abstract

“…As far as soft tissues metastatic disease is concerned outcomes upon all ablative techniques have been reported highlighting that percutaneous ablation is a safe and efficacious therapy for both palliative and curative intent [ 47 , 48 , 49 , 50 ]. Once again studies focusing upon soft tissues sarcoma metastatic disease are governed by heterogeneity of the patient populations with respect to histologic subtype, location of treatment, combination to other therapies and ablation modality used.…”

Section: Thermal Ablation Of Bone Metastasismentioning

confidence: 99%

Ablative Techniques for Sarcoma Metastatic Disease: Current Role and Clinical Applications

et al. 2023

View full text Add to dashboard Cite

Sarcomas are heterogenous mesenchymal neoplasms with more than 80 different histologic subtypes. Lung followed by liver and bone are the most common sites of sarcoma metastatic disease. Ablative techniques have been recently added as an additional alternative curative or palliative therapeutic tool in sarcoma metastatic disease. When compared to surgery, ablative techniques are less invasive therapies which can be performed even in non-surgical candidates and are related to decreased recovery time as well as preservation of the treated organ’s long-term function. Literature data upon ablative techniques for sarcoma metastatic disease are quite heterogeneous and variable regarding the size and the number of the treated lesions and the different histologic subtypes of the original soft tissue or bone sarcoma. The present study focuses upon the current role of minimal invasive thermal ablative techniques for the management of metastatic sarcoma disease. The purpose of this review is to present the current minimally invasive ablative techniques in the treatment of metastatic soft tissue and bone sarcoma, including local control and survival rates.

show abstract

Initial Experience: Alleviation of Pain with Percutaneous CT–Guided Cryoablation for Recurrent Retroperitoneal Soft-Tissue Sarcoma

Cited by 12 publications

References 22 publications

Cryoablation for malignant bone and soft tissue tumors and histological assessment of ablated tumors

Cryoablation for malignant bone and soft tissue tumors and histological assessment of ablated tumors

Current Technique and Application of Percutaneous Cryotherapy

Ablative Techniques for Sarcoma Metastatic Disease: Current Role and Clinical Applications

Contact Info

Product

Resources

About